Seegene has developed a molecular assay for the quantification of 21 respiratory viral pathogens associated with respiratory disease. The assay, called QuantPlex RV-16, will give physicians the specific information needed to guide patient treatment decisions, and aims to answer questions that previously have gone unasked and/or unanswered.
The majority of respiratory infections (approximately 80 per cent) are viral in nature. Within the paediatric population, respiratory viral infections account for a considerable proportion of Accident & Emergency room visits. The company says that accurate and reliable detection and differentiation of these respiratory viral pathogens is needed to assess and treat a patient's particular disease state. Conventional detection methods for respiratory viral pathogen detection include rapid point-of-care immunoassays and cell culture in combination with direct immunofluorescence assays. With the 2009 H1N1 pandemic, nucleic acid detection methods have started to become the accepted standard for the diagnosis of respiratory viral infections.
Comparative studies have shown that for the detection of respiratory viruses, real-time reverse transcriptase - polymerase chain reaction (RT-PCR) is significantly more sensitive and specific than certain conventional detection methods. Current commercially available RT-PCR detection assays for respiratory viruses, however, can only provide qualitative information. These qualitative real-time RT-PCR viral respiratory assays are still limited in their ability to discriminate between current infections versus the shedding of low concentrations of virus from previous infections. This inability to discriminate infections also limits physicians' ability to guide the treatment of co-infections.
In contrast, Seegene believes that a quantitative real-time RT-PCR respiratory viral assay provides both a qualitative answer, as well as quantitative information concerning each analyte detected. The advantages of a quantitative real-time RT-PCR respiratory viral assay is that it permits the assessment of pathogen load at a given point in time, facilitates the monitoring of response to treatment, and offers the ability to determine the dynamics of the viruses proliferation.
The QuantPlex RV-16 assay can detect, differentiate and provide quantitative information for adenovirus, influenza A and B, para-influenza virus types 1/2/3/4, rhinovirus types A/B/C, respiratory syncytial viruses A and B, bocavirus 1/2/3/4, metapneumovirus, coronavirus types 229E, NL63, OC43 and enterovirus from a single sample, all in real-time. The assay is based on Seegene's TOCE-CCMTA technology, a high multiplex real-time quantitative PCR technology that enables the simultaneous detection, differentiation and quantification of up to 20 analytes on an existing four-colour real-time instrument.